Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant.

Katharina WilluweitAndreas HeinoldJassin Rashidi-AlavijehFalko M HeinemannPeter A HornAndreas PaulGuido GerkenKerstin Herzer

Published in: Clinical transplantation (2017)

Autoimmune liver diseases, female sex, and time of more than 8 years since LT predispose patients to the development of DSAs. Immunosuppression with the mTOR inhibitor everolimus protects against DSA development after liver transplant.

Keyphrases

end stage renal disease
ejection fraction
cell proliferation
newly diagnosed
multiple sclerosis
prognostic factors
patient reported